Movers and SHAKERS
ProMIS Neurosciences Inc. (PMN:CA)
Progress Made in Q3 Bodes Well for ProMIS' Prospects
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform—ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody for AD; PMN350, a monoclonal antibody for AD; and PMN330, a monoclonal antibody targeting toxic prionlike forms of AßO for AD. The company is also developing prospect therapies targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS and frontotemporal dementia, as well as alpha synuclein in Parkinson’s disease and Lewy body dementia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Cosme Ordonez, MD, Ph.D., Senior Life Sciences Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- ProMIS advances R&D Programs. ProMIS Neurosciences yesterday announced results for Q3/F2019. In the quarter, the company advanced preclinical development of lead Alzheimer’s drug PMN310, and generated novel antibody candidates for the treatment of other neurodegenerative diseases known as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
- ProMIS' differentiation. ProMIS Neurosciences is developing a novel therapeutic approach targeting a distinctive molecular entity, known as toxic oligomers, which the scientific literature recognizes as the true culprits of...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.